US4265814A
(en)
*
|
1978-03-24 |
1981-05-05 |
Takeda Chemical Industries |
Matansinol 3-n-hexadecanoate
|
US4307016A
(en)
*
|
1978-03-24 |
1981-12-22 |
Takeda Chemical Industries, Ltd. |
Demethyl maytansinoids
|
JPS5562090A
(en)
*
|
1978-10-27 |
1980-05-10 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS5566585A
(en)
*
|
1978-11-14 |
1980-05-20 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS55164687A
(en)
*
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS5566586A
(en)
*
|
1978-11-14 |
1980-05-20 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
US4256746A
(en)
*
|
1978-11-14 |
1981-03-17 |
Takeda Chemical Industries |
Dechloromaytansinoids, their pharmaceutical compositions and method of use
|
US4263294A
(en)
*
|
1978-11-20 |
1981-04-21 |
Takeda Chemical Industries, Ltd. |
Maytansinoids, pharmaceutical compositions thereof and method of use thereof
|
JPS55102583A
(en)
*
|
1979-01-31 |
1980-08-05 |
Takeda Chem Ind Ltd |
20-acyloxy-20-demethylmaytansinoid compound
|
JPS55162791A
(en)
*
|
1979-06-05 |
1980-12-18 |
Takeda Chem Ind Ltd |
Antibiotic c-15003pnd and its preparation
|
JPS55164685A
(en)
*
|
1979-06-08 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS55164686A
(en)
*
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS5622790A
(en)
*
|
1979-07-31 |
1981-03-03 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS5645483A
(en)
*
|
1979-09-19 |
1981-04-25 |
Takeda Chem Ind Ltd |
C-15003phm and its preparation
|
US4315929A
(en)
*
|
1981-01-27 |
1982-02-16 |
The United States Of America As Represented By The Secretary Of Agriculture |
Method of controlling the European corn borer with trewiasine
|
US5208020A
(en)
*
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
MXPA01013240A
(es)
|
1999-06-25 |
2002-06-21 |
Genentech Inc |
Metodo de tratamiento utilizando conjugados de anticuerpo contra erbb-maytansionoide.
|
AU775373B2
(en)
|
1999-10-01 |
2004-07-29 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
US7589180B2
(en)
|
2001-05-11 |
2009-09-15 |
Abbott Laboratories Inc. |
Specific binding proteins and uses thereof
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
US7803915B2
(en)
*
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
ES2372321T3
(es)
|
2001-06-20 |
2012-01-18 |
Genentech, Inc. |
Composiciones y métodos para el diagnóstico y tratamiento de un tumor de pulmón.
|
US20050107595A1
(en)
*
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US20080085283A1
(en)
*
|
2001-09-05 |
2008-04-10 |
Levinson Arthur D |
Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
|
US20040235068A1
(en)
*
|
2001-09-05 |
2004-11-25 |
Levinson Arthur D. |
Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
|
NZ531674A
(en)
|
2001-09-18 |
2009-03-31 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor
|
US20110045005A1
(en)
|
2001-10-19 |
2011-02-24 |
Craig Crowley |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
KR20070087247A
(ko)
|
2002-01-02 |
2007-08-27 |
제넨테크, 인크. |
종양의 진단 및 치료 방법 및 이를 위한 조성물
|
CA2481507A1
(fr)
|
2002-04-16 |
2003-10-30 |
Genentech, Inc. |
Compositions et methodes permettant de diagnostiquer et de traiter une tumeur
|
US20090068178A1
(en)
*
|
2002-05-08 |
2009-03-12 |
Genentech, Inc. |
Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
|
US20040249130A1
(en)
*
|
2002-06-18 |
2004-12-09 |
Martin Stanton |
Aptamer-toxin molecules and methods for using same
|
US20040022727A1
(en)
*
|
2002-06-18 |
2004-02-05 |
Martin Stanton |
Aptamer-toxin molecules and methods for using same
|
US7767803B2
(en)
|
2002-06-18 |
2010-08-03 |
Archemix Corp. |
Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
|
US8853376B2
(en)
|
2002-11-21 |
2014-10-07 |
Archemix Llc |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
US7432088B2
(en)
|
2003-05-08 |
2008-10-07 |
Immunogen Inc. |
Methods for the production of ansamitocins
|
EP1633784B1
(fr)
|
2003-05-09 |
2011-07-13 |
Diadexus, Inc. |
Compositions d'anticorps anti-ovr110, et leur procede d'utilisation
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
PT3524611T
(pt)
|
2003-05-20 |
2021-04-01 |
Immunogen Inc |
Agentes citotóxicos melhorados compreendendo novos maitansinóides
|
BRPI0411803A
(pt)
|
2003-06-27 |
2006-05-23 |
Abgenix Inc |
anticorpos dirigidos aos mutantes de deleção de receptor de fator de crescimento epidérmico e seus usos
|
SI2784084T2
(sl)
|
2003-07-08 |
2024-02-29 |
Novartis Pharma Ag |
Antagonistična protitelesa proti IL-17 A/F heterolognim polipeptidom
|
KR20060069825A
(ko)
*
|
2003-08-01 |
2006-06-22 |
제넨테크, 인크. |
제한된 다양성을 갖는 항체 cdr 폴리펩티드 서열
|
JP4901478B2
(ja)
|
2003-11-17 |
2012-03-21 |
ジェネンテック, インコーポレイテッド |
造血系起源の腫瘍の治療のための組成物と方法
|
PL1718677T3
(pl)
|
2003-12-19 |
2012-09-28 |
Genentech Inc |
Jednowartościowe fragmenty przeciwciała stosowane jako środki lecznicze
|
EP2286844A3
(fr)
*
|
2004-06-01 |
2012-08-22 |
Genentech, Inc. |
Conjugués anticorps-médicament et procédés
|
PL1771474T3
(pl)
|
2004-07-20 |
2010-07-30 |
Genentech Inc |
Inhibitory białka angiopoetyno-4-podobnego, kombinacje i ich zastosowanie
|
JP5226308B2
(ja)
|
2004-07-26 |
2013-07-03 |
ジェネンテック, インコーポレイテッド |
肝細胞増殖因子活性化を制御するための方法及び組成物
|
CA2486285C
(fr)
*
|
2004-08-30 |
2017-03-07 |
Viktor S. Goldmakher |
Immunoconjugues ciblant des cellules a expression du syndecan-1 et utilisation de ceux-ci
|
HUE058817T2
(hu)
*
|
2004-09-03 |
2022-09-28 |
Genentech Inc |
Humanizált anti-béta7 antagonisták és alkalmazásaik
|
JP2008526883A
(ja)
|
2005-01-07 |
2008-07-24 |
ディアデクサス インコーポレーテッド |
Ovr110抗体組成物および使用方法
|
CA2600418A1
(fr)
*
|
2005-03-07 |
2006-09-14 |
Archemix Corp. |
Aptameres stabilises d'apsm et leur utilisation comme agents therapeutiques contre le cancer de la prostate
|
US7858843B2
(en)
|
2005-06-06 |
2010-12-28 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
AU2006280321A1
(en)
|
2005-08-15 |
2007-02-22 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
AU2006283726C1
(en)
|
2005-08-24 |
2015-05-07 |
Immunogen, Inc. |
Process for preparing maytansinoid antibody conjugates
|
EP2465870A1
(fr)
|
2005-11-07 |
2012-06-20 |
Genentech, Inc. |
Polypeptides de liaison dotés de séquences hypvervariables VH/VL diversifiées et consensuelles
|
AU2006335053A1
(en)
|
2005-11-21 |
2007-07-19 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
AU2006342792A1
(en)
|
2005-12-02 |
2007-11-08 |
Genentech, Inc. |
Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R
|
KR101434682B1
(ko)
*
|
2005-12-02 |
2014-08-27 |
제넨테크, 인크. |
결합 폴리펩티드 및 이들의 용도
|
US20070237764A1
(en)
*
|
2005-12-02 |
2007-10-11 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
KR101538521B1
(ko)
|
2005-12-15 |
2015-07-22 |
제넨테크, 인크. |
폴리유비퀴틴 표적화를 위한 방법 및 조성물
|
DK1973950T3
(en)
|
2006-01-05 |
2014-12-15 |
Genentech Inc |
ANTI-EphB4 ANTIBODIES AND METHODS FOR USING SAME
|
EP1806365A1
(fr)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Anticorps spécifiques pour la protéine alpha d'activation de fibroblastes et leurs immunoconjugués
|
RU2451031C2
(ru)
|
2006-01-20 |
2012-05-20 |
Дженентек, Инк. |
Антитела к эфрину в2 и способы их применения
|
EP2050335A1
(fr)
|
2006-02-17 |
2009-04-22 |
Genentech, Inc. |
Dislocation de gènes, compositions et procédés correspondants
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
EP2614839A3
(fr)
|
2006-04-05 |
2015-01-28 |
Genentech, Inc. |
Méthode d'utilisation du BOC/CDO pour moduler l'émission des signaux du hedgehog
|
EP2082645A1
(fr)
|
2006-04-19 |
2009-07-29 |
Genentech, Inc. |
Nouvelle dislocation de gènes, compositions et procédés correspondants
|
MX2008015132A
(es)
|
2006-05-30 |
2008-12-10 |
Genentech Inc |
Anticuerpos e inmunoconjugados y sus usos.
|
ATE522625T1
(de)
|
2006-09-12 |
2011-09-15 |
Genentech Inc |
Verfahren und zusammensetzungen zur diagnose und behandlung von lungenkrebs mittels pdgfra-, kit- oder kdg-gen als genmarker
|
EP2061814B1
(fr)
|
2006-10-27 |
2012-06-06 |
Genentech, Inc. |
Anticorps et immunoconjugues, et leurs utilisations
|
JP5391073B2
(ja)
|
2006-11-27 |
2014-01-15 |
ディアデクサス インコーポレーテッド |
Ovr110抗体組成物および使用方法
|
US9090693B2
(en)
*
|
2007-01-25 |
2015-07-28 |
Dana-Farber Cancer Institute |
Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
|
CA2676766A1
(fr)
|
2007-02-09 |
2008-08-21 |
Genentech, Inc. |
Anticorps anti-robo4 et utilisations de ceux-ci
|
JP5618549B2
(ja)
*
|
2007-03-15 |
2014-11-05 |
ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド |
Egfr抗体及びsrc阻害剤を用いる治療方法及び関連製剤
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
PE20090321A1
(es)
|
2007-06-04 |
2009-04-20 |
Genentech Inc |
Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
|
WO2009012256A1
(fr)
|
2007-07-16 |
2009-01-22 |
Genentech, Inc. |
Anticorps anti-cd79b humanisés, immunoconjugués, et procédés d'utilisation
|
DK2474557T3
(da)
|
2007-07-16 |
2014-11-10 |
Genentech Inc |
Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
|
JP5532486B2
(ja)
|
2007-08-14 |
2014-06-25 |
ルードヴィッヒ インスティテュート フォー キャンサー リサーチ |
Egf受容体を標的とするモノクローナル抗体175ならびにその誘導体および用途
|
PT2220116E
(pt)
*
|
2007-11-12 |
2012-12-07 |
Theraclone Sciences Inc |
Composições e métodos para a terapia e o diagnóstico da gripe
|
US20110033476A1
(en)
*
|
2007-11-12 |
2011-02-10 |
Theraclone Sciences Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
AR069501A1
(es)
|
2007-11-30 |
2010-01-27 |
Genentech Inc |
Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
|
JP5990365B2
(ja)
|
2007-12-26 |
2016-09-14 |
バイオテスト・アクチエンゲゼルシヤフト |
Cd138を標的とする剤及びその使用
|
WO2009080831A1
(fr)
*
|
2007-12-26 |
2009-07-02 |
Biotest Ag |
Procédé permettant de réduire les effets secondaires cytotoxiques et d'améliorer l'efficacité des immunoconjugués
|
JP5817034B2
(ja)
*
|
2007-12-26 |
2015-11-18 |
バイオテスト・アクチエンゲゼルシヤフト |
Cd138を標的とする免疫複合体及びその使用
|
MX2010007101A
(es)
*
|
2007-12-26 |
2011-07-01 |
Biotest Ag |
Metodos y agentes para mejorar el reconocimiento de celulas de tumor que expresan cd138.
|
CN101977934B
(zh)
|
2008-01-18 |
2014-09-17 |
健泰科生物技术公司 |
用于靶向k63连接的多聚遍在蛋白的方法和组合物
|
DK2657253T3
(en)
|
2008-01-31 |
2017-10-09 |
Genentech Inc |
Anti-CD79b antibodies and immune conjugates and methods of use
|
EP2257571B1
(fr)
|
2008-03-10 |
2015-03-04 |
Theraclone Sciences, Inc. |
Compositions et procédés pour le diagnostic et le traitement d'une infection à cytomégalovirus
|
EP2644204B1
(fr)
|
2008-03-18 |
2017-04-19 |
Genentech, Inc. |
Combinaisons de conjugué de médicament-anticorps anti-HER2 et du pertuzumab
|
SG10201402815VA
(en)
|
2008-04-09 |
2014-09-26 |
Genentech Inc |
Novel compositions and methods for the treatment of immune related diseases
|
EP2279004B1
(fr)
*
|
2008-05-16 |
2015-01-14 |
F. Hoffmann-La Roche AG |
Utilisation de biomarqueurs pour évaluer le traitement de troubles inflammatoires gastro-intestinaux avec des antagonistes de l'intégrine bêta7
|
EP2318832B1
(fr)
|
2008-07-15 |
2013-10-09 |
Academia Sinica |
Matrices de glycane sur des lames de verre revêtues d' aluminium de type ptfe et procédés associés
|
CN102170909B
(zh)
|
2008-10-01 |
2015-11-25 |
霍夫曼-拉罗奇有限公司 |
抗-notch2抗体和使用方法
|
WO2010080528A1
(fr)
|
2008-12-17 |
2010-07-15 |
Genentech, Inc. |
Polythérapie contre le virus de l'hépatite c
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
CN104447995A
(zh)
|
2009-03-20 |
2015-03-25 |
霍夫曼-拉罗奇有限公司 |
双特异性抗-her抗体
|
SI3702371T1
(sl)
*
|
2009-03-25 |
2023-01-31 |
Genentech, Inc. |
Protitelesa proti FGFR3 in postopki za uporabo le-teh
|
US8466260B2
(en)
|
2009-04-01 |
2013-06-18 |
Genentech, Inc. |
Anti-FcRH5 antibodies and immunoconjugates and methods of use
|
MX2011010159A
(es)
|
2009-04-02 |
2011-10-17 |
Roche Glycart Ag |
Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla.
|
US8609101B2
(en)
*
|
2009-04-23 |
2013-12-17 |
Theraclone Sciences, Inc. |
Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies
|
EP2432803A2
(fr)
|
2009-05-20 |
2012-03-28 |
Theraclone Sciences, Inc. |
Compositions et procédés pour le traitement et le diagnostic de la grippe
|
SG10201810743WA
(en)
|
2009-06-03 |
2018-12-28 |
Immunogen Inc |
Conjugation methods
|
EP2711018A1
(fr)
|
2009-06-22 |
2014-03-26 |
MedImmune, LLC |
Régions Fc modifiées pour conjugaison spécifique d'un site
|
KR20120089253A
(ko)
|
2009-07-31 |
2012-08-09 |
제넨테크, 인크. |
Bv8? 또는 g?csf?길항제를 이용한 종양 전이의 억제
|
EP2473522B1
(fr)
|
2009-09-02 |
2016-08-17 |
Genentech, Inc. |
Mutant smoothened et ses méthodes d'utilisation
|
WO2011034605A2
(fr)
|
2009-09-16 |
2011-03-24 |
Genentech, Inc. |
Complexes protéiques contenant une super-hélice et/ou une attache et leurs utilisations
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
AR078471A1
(es)
|
2009-10-02 |
2011-11-09 |
Sanofi Aventis |
COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS
|
KR20120106940A
(ko)
|
2009-10-19 |
2012-09-27 |
제넨테크, 인크. |
간세포 성장 인자 활성화제의 조절제
|
BR112012009409A2
(pt)
|
2009-10-22 |
2017-02-21 |
Genentech Inc |
método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
|
EP2491059B1
(fr)
|
2009-10-22 |
2015-02-25 |
F.Hoffmann-La Roche Ag |
Anticorps anti-hepsine et procédés d'utilisation de ceux-ci
|
WO2011056497A1
(fr)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Compositions de récepteur de l'activine de type iib et leurs méthodes d'utilisation
|
WO2011056494A1
(fr)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Combinaisons d'antagonistes de la kinase-1 du type récepteur de l'activine et d'antagonistes vegfr3
|
WO2011056502A1
(fr)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Compositions du gene recepteur de proteine morphogenetique osseuse type ii et procedes d'utilisation
|
BR112012010153B1
(pt)
|
2009-11-05 |
2022-05-03 |
Genentech, Inc |
Método de produção de um anticorpo
|
SG10201408598XA
(en)
|
2009-11-30 |
2015-02-27 |
Genentech Inc |
Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US8486397B2
(en)
|
2009-12-11 |
2013-07-16 |
Genentech, Inc. |
Anti-VEGF-C antibodies and methods using same
|
CA2784385A1
(fr)
|
2009-12-23 |
2011-06-30 |
Genentech, Inc. |
Anticorps anti-bv8 et leurs utilisations
|
US20110159588A1
(en)
|
2009-12-30 |
2011-06-30 |
Kui Lin |
Methods for Modulating a PDGF-AA Mediated Biological Response
|
MA34057B1
(fr)
|
2010-02-23 |
2013-03-05 |
Genentech Inc |
Compositions et methodes pour le diagnostic et le traitement d'une tumeur
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
US10338069B2
(en)
|
2010-04-12 |
2019-07-02 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
WO2011133886A2
(fr)
|
2010-04-23 |
2011-10-27 |
Genentech, Inc. |
Production de protéines hétéromultimères
|
PE20130460A1
(es)
|
2010-05-03 |
2013-04-26 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores
|
MX336109B
(es)
|
2010-06-03 |
2016-01-08 |
Genentech Inc |
Formacion de imagenes inmuno-tep de anticuerpos e inmunoconjugados y usos de lo mismo.
|
JP2013540701A
(ja)
|
2010-08-12 |
2013-11-07 |
セラクローン サイエンシーズ, インコーポレイテッド |
抗赤血球凝集素抗体組成物およびその使用方法
|
CN103068846B9
(zh)
|
2010-08-24 |
2016-09-28 |
弗·哈夫曼-拉罗切有限公司 |
包含二硫键稳定性Fv片段的双特异性抗体
|
EP2926830B1
(fr)
|
2010-08-31 |
2017-08-02 |
Theraclone Sciences, Inc. |
Anticorps de neutralisation du virus de l'immunodéficience humaine (vih)
|
JP5866130B2
(ja)
|
2010-09-10 |
2016-02-17 |
アペクシジェン, インコーポレイテッド |
抗IL−1β抗体およびその使用方法
|
DK2625197T3
(en)
|
2010-10-05 |
2016-10-03 |
Genentech Inc |
Smoothened MUTANT AND METHODS OF USING THE SAME
|
ES2544608T3
(es)
|
2010-11-17 |
2015-09-02 |
Genentech, Inc. |
Conjugados de anticuerpo y de alaninil-maitansinol
|
WO2012085111A1
(fr)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Complexe polypeptide-polynucléotide et son utilisation dans l'administration d'une fraction effectrice ciblée
|
WO2012092539A2
(fr)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Anticorps contre dll4 et leurs utilisations
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
BR112013019499B1
(pt)
|
2011-02-04 |
2023-01-10 |
Genentech, Inc. |
Proteína heteromultimérica variante ou anticorpo igg modificado, método para produzir uma proteína heteromultimérica variante ou anticorpo igg modificado, composição, método para preparar uma proteína heteromultimérica e proteína heteromultimérica variante
|
BR112013020743A2
(pt)
|
2011-02-14 |
2016-10-18 |
Theraclone Sciences Inc |
composições e métodos para a terapia e diagnóstico de influenza
|
KR20140043724A
(ko)
|
2011-03-03 |
2014-04-10 |
아펙시젠, 인코포레이티드 |
항-il-6 수용체 항체 및 사용 방법
|
US20120315277A1
(en)
|
2011-03-15 |
2012-12-13 |
Theraclone Sciences, Inc. |
Compositions and Methods for the Therapy and Diagnosis of Influenza
|
SI2691155T1
(sl)
|
2011-03-29 |
2019-03-29 |
Immunogen, Inc. |
Priprava majtanzinoidnih konjugatov protiteles v postopku z enim korakom
|
JP6125489B2
(ja)
|
2011-04-29 |
2017-05-10 |
アペクシジェン, インコーポレイテッド |
抗cd40抗体および使用方法
|
MX2013013104A
(es)
|
2011-05-09 |
2014-10-15 |
Univ Virginia Patent Found |
Composiciones y metodos para el tratamiento de cancer.
|
DK3415531T3
(da)
|
2011-05-27 |
2023-09-18 |
Glaxo Group Ltd |
Bcma (cd269/tnfrsf17)-bindende proteiner
|
RU2014109985A
(ru)
|
2011-08-17 |
2015-09-27 |
Дженентек, Инк. |
Ингибирование ангиогенеза в рефрактерных опухолях
|
US8822651B2
(en)
|
2011-08-30 |
2014-09-02 |
Theraclone Sciences, Inc. |
Human rhinovirus (HRV) antibodies
|
EP2758437B1
(fr)
|
2011-09-22 |
2020-06-03 |
Amgen Inc. |
Protéines de liaison à un antigène cd27l
|
MX2014004991A
(es)
|
2011-10-28 |
2014-05-22 |
Genentech Inc |
Combinaciones terapeuticas y metodos para tratar el melanoma.
|
WO2013067098A1
(fr)
|
2011-11-02 |
2013-05-10 |
Apexigen, Inc. |
Anticorps anti-kdr et procédés d'utilisation
|
KR20140091064A
(ko)
|
2011-11-16 |
2014-07-18 |
암젠 인크 |
표피 성장 인자 결실 돌연변이체 vⅲ 관련 장애를 치료하는 방법
|
MX358680B
(es)
|
2011-12-08 |
2018-08-31 |
Biotest Ag |
Usos de inmunoconjugados dirigidos a cd138.
|
CA2859755C
(fr)
|
2011-12-23 |
2021-04-20 |
Pfizer Inc. |
Regions constantes d'anticorps modifies pour conjugaison specifique a un site, et leurs procedes et utilisations
|
WO2013106485A2
(fr)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Régions déterminant la complémentarité ultralongues et utilisations associées
|
JP2015509091A
(ja)
|
2012-01-09 |
2015-03-26 |
ザ スクリプス リサーチ インスティテュート |
ヒト化抗体
|
RU2644341C2
(ru)
|
2012-02-10 |
2018-02-08 |
Дженентек, Инк. |
Одноцепочечные антитела и другие гетеромультимеры
|
AU2013229786B2
(en)
|
2012-03-08 |
2017-06-22 |
Halozyme, Inc. |
Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
CA2867824A1
(fr)
|
2012-05-01 |
2013-11-07 |
Genentech, Inc. |
Anticorps anti-pmel17 et immunoconjugues
|
UY34813A
(es)
|
2012-05-18 |
2013-11-29 |
Amgen Inc |
Proteínas de unión a antígeno dirigidas contra el receptor st2
|
EP2867253B1
(fr)
|
2012-06-27 |
2016-09-14 |
F. Hoffmann-La Roche AG |
Méthode de sélection et de production d'entités de ciblage personnalisées fortement sélectives et multi-spécifiques renfermant au moins deux entités de liaison différentes et leurs utilisations
|
CA2871882A1
(fr)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Methode de fabrication de conjugues d'anticorps a region fc comprenant au moins une entite de liaison qui se lie specifiquement a une cible et leurs utilisations
|
US9914956B2
(en)
|
2012-08-18 |
2018-03-13 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
HUE055443T2
(hu)
|
2012-09-26 |
2021-11-29 |
Immunogen Inc |
Javított eljárások maytansinol acilezéséhez
|
SG10201702737TA
(en)
|
2012-10-04 |
2017-05-30 |
Immunogen Inc |
Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
|
AU2013337903B2
(en)
|
2012-10-30 |
2018-08-16 |
Apexigen, Inc. |
Anti-CD40 antibodies and methods of use
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Bcma抗原結合蛋白質
|
CN104650113A
(zh)
|
2012-12-21 |
2015-05-27 |
百奥泰生物科技(广州)有限公司 |
类美登素衍生物及其制备方法和用途
|
CN103333246B
(zh)
|
2012-12-21 |
2015-09-16 |
百奥泰生物科技(广州)有限公司 |
一种抗egfr受体的肿瘤生长抑制剂及其制备方法和用途
|
CN103254213B
(zh)
|
2012-12-21 |
2015-02-25 |
百奥泰生物科技(广州)有限公司 |
类美登素酯的制备方法及用于所述方法的组合物
|
CN103288957B
(zh)
|
2012-12-21 |
2015-01-28 |
百奥泰生物科技(广州)有限公司 |
一种抑制肿瘤生长的抗体药物衍生物及其制备方法和用途
|
EP2948478B1
(fr)
|
2013-01-25 |
2019-04-03 |
Amgen Inc. |
Anticorps ciblant cdh19 pour un mélanome
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
MX2015010777A
(es)
|
2013-03-14 |
2016-04-25 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-b7-h4.
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
AP2015008656A0
(en)
|
2013-03-15 |
2015-08-31 |
Novartis Ag |
Antibody drug conjugates
|
EA201592285A1
(ru)
|
2013-05-30 |
2016-05-31 |
Байоджен Ма Инк. |
Антигенсвязывающие белки к рецептору онкостатина м
|
EP3013365B1
(fr)
|
2013-06-26 |
2019-06-05 |
Academia Sinica |
Antigènes rm2 et leur utilisation
|
WO2014210564A1
(fr)
|
2013-06-27 |
2014-12-31 |
Academia Sinica |
Conjugués de glycane et leur utilisation
|
WO2015017146A2
(fr)
|
2013-07-18 |
2015-02-05 |
Fabrus, Inc. |
Anticorps à régions de détermination de complémentarité ultralongues
|
CN111518199A
(zh)
|
2013-07-18 |
2020-08-11 |
图鲁斯生物科学有限责任公司 |
具有超长互补决定区的人源化抗体
|
EP3738612A1
(fr)
|
2013-07-31 |
2020-11-18 |
Biontech AG |
Diagnostic et traitement du cancer impliquant des cellules souches cancéreuses
|
CN104341504B
(zh)
|
2013-08-06 |
2017-10-24 |
百奥泰生物科技(广州)有限公司 |
双特异性抗体
|
US9782476B2
(en)
|
2013-09-06 |
2017-10-10 |
Academia Sinica |
Human iNKT cell activation using glycolipids with altered glycosyl groups
|
MX2016003256A
(es)
|
2013-09-12 |
2016-06-07 |
Halozyme Inc |
Anticuerpos modificados del receptor de factor de crecimiento anti-epidermico y metodos de uso de los mismos.
|
KR20160055252A
(ko)
|
2013-09-17 |
2016-05-17 |
제넨테크, 인크. |
항-lgr5 항체의 사용 방법
|
ES2960807T3
(es)
|
2013-10-11 |
2024-03-06 |
Us Health |
Anticuerpos contra TEM8 y su uso
|
US20160280798A1
(en)
|
2013-11-06 |
2016-09-29 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Service |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
US9562059B2
(en)
*
|
2013-12-02 |
2017-02-07 |
Hong Kong Baptist University |
Anticancer maytansinoids with two fused macrocyclic rings
|
EA201691214A1
(ru)
|
2013-12-13 |
2016-12-30 |
Дженентек, Инк. |
Антитела к cd33 и иммуноконъюгаты
|
EP3082875B1
(fr)
|
2013-12-16 |
2020-11-25 |
Genentech, Inc. |
Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
JP2017507118A
(ja)
|
2014-01-16 |
2017-03-16 |
アカデミア シニカAcademia Sinica |
がんの処置および検出のための組成物および方法
|
RU2016130349A
(ru)
|
2014-01-24 |
2018-03-01 |
Дженентек, Инк. |
Способы применения антител против steap1 и иммуноконъюгатов
|
WO2015120075A2
(fr)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened et méthodes d'utilisation de celui-ci
|
TWI687428B
(zh)
|
2014-03-27 |
2020-03-11 |
中央研究院 |
反應性標記化合物及其用途
|
JP2017512765A
(ja)
|
2014-04-11 |
2017-05-25 |
メディミューン,エルエルシー |
二重特異性her2抗体
|
ES2955736T3
(es)
|
2014-05-06 |
2023-12-05 |
Hoffmann La Roche |
Producción de proteínas heteromultiméricas usando células de mamífero
|
CN106414499A
(zh)
|
2014-05-22 |
2017-02-15 |
基因泰克公司 |
抗gpc3抗体和免疫偶联物
|
KR102512592B1
(ko)
|
2014-05-27 |
2023-03-21 |
아카데미아 시니카 |
항-her2 글리코항체 및 이의 용도
|
CA2950415A1
(fr)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Glycoanticorps anti-cd20 et leurs utilisations
|
EP3149045B1
(fr)
|
2014-05-27 |
2023-01-18 |
Academia Sinica |
Compositions et procédés concernant des glycoformes universelles pour une efficacité d'anticorps améliorée
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
KR102494193B1
(ko)
|
2014-05-28 |
2023-01-31 |
아카데미아 시니카 |
항-tnf-알파 글리코항체 및 이의 용도
|
MX2017001946A
(es)
|
2014-08-12 |
2017-06-19 |
Novartis Ag |
Conjugados de farmacos con anticuerpos anti-cdh6.
|
US20170260261A1
(en)
|
2014-08-28 |
2017-09-14 |
Bioatla, Llc |
Conditionally Active Chimeric Antigen Receptors for Modified T-Cells
|
KR102422375B1
(ko)
|
2014-09-08 |
2022-07-18 |
아카데미아 시니카 |
당지질을 사용한 인간 iNKT 세포 활성화
|
US10059768B2
(en)
|
2014-09-12 |
2018-08-28 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
TWI758784B
(zh)
|
2014-09-12 |
2022-03-21 |
美商建南德克公司 |
抗her2抗體及免疫結合物
|
CA2958479A1
(fr)
|
2014-09-12 |
2016-03-17 |
Genentech, Inc. |
Anticorps anti-cll-1 et immunoconjugues
|
PT3262071T
(pt)
|
2014-09-23 |
2020-06-16 |
H Hoffnabb La Roche Ag |
Métodos de utilização de imunoconjugados anti-cd79b
|
AU2015324924B2
(en)
|
2014-10-01 |
2021-07-01 |
Medimmune, Llc |
Method of conjugating a polypeptide
|
MX2017003478A
(es)
|
2014-11-05 |
2018-02-01 |
Genentech Inc |
Anticuerpos anti-fgfr2/3 y metodos para su uso.
|
CN107001482B
(zh)
|
2014-12-03 |
2021-06-15 |
豪夫迈·罗氏有限公司 |
多特异性抗体
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
EP3248013B1
(fr)
|
2015-01-24 |
2020-07-15 |
Academia Sinica |
Marqueurs de cancer et leurs procédés d'utilisation
|
EP3248005B1
(fr)
|
2015-01-24 |
2020-12-09 |
Academia Sinica |
Nouveaux composés conjugués de glycane et leurs méthodes d'utilisation
|
CA2975875A1
(fr)
|
2015-02-04 |
2016-08-11 |
Genentech, Inc. |
Mutant smoothened et methodes d'utilisation de celui-ci
|
CN107614020A
(zh)
|
2015-03-18 |
2018-01-19 |
免疫生化公司 |
靶向细胞内肿瘤相关抗原的用于治疗癌症的缀合物
|
WO2016165762A1
(fr)
|
2015-04-15 |
2016-10-20 |
Ganymed Pharmaceuticals Ag |
Conjugués de médicaments comprenant des anticorps contre la claudine 18.2
|
KR20240093813A
(ko)
|
2015-04-24 |
2024-06-24 |
제넨테크, 인크. |
다중특이적 항원-결합 단백질
|
AU2016277121C1
(en)
|
2015-06-12 |
2022-07-14 |
Lentigen Technology, Inc. |
Method to treat cancer with engineered T-cells
|
EP3310813A1
(fr)
|
2015-06-17 |
2018-04-25 |
Novartis AG |
Conjugués anticorps-médicament
|
EP3359562B1
(fr)
|
2015-10-09 |
2019-12-04 |
Miltenyi Biotec Technology, Inc. |
Récepteur d'antigène chimérique et ses utilisations
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
JP6991978B2
(ja)
|
2016-01-27 |
2022-02-03 |
メディミューン,エルエルシー |
定められるグリコシル化パターンを有する抗体を調製するための方法
|
CA3019952A1
(fr)
|
2016-02-04 |
2017-08-10 |
Curis, Inc. |
Mutant smoothened et methodes d'utilisation dudit mutant
|
JP2019515876A
(ja)
|
2016-03-08 |
2019-06-13 |
アカデミア シニカAcademia Sinica |
N−グリカンおよびそのアレイのモジュール合成のための方法
|
WO2017161206A1
(fr)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugués contenant des anticorps à activité conditionnelle ou des fragments de liaison à un antigène associés, et procédés d'utilisation
|
CN109563164A
(zh)
|
2016-04-15 |
2019-04-02 |
生物蛋白有限公司 |
抗axl抗体、抗体片段和它们的免疫缀合物以及其用途
|
PE20190353A1
(es)
|
2016-04-15 |
2019-03-07 |
Macrogenics Inc |
Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos
|
WO2017196847A1
(fr)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticorps anti-nouveau récepteur variable d'antigène (vnar) et conjugués d'anticorps ciblant des antigènes tumoraux et viraux
|
HRP20221298T1
(hr)
|
2016-05-13 |
2022-12-23 |
Bioatla, Inc. |
Anti-ror2 protutijela, fragmenti protutijela, njihovi imunokonjugati i njihove uporabe
|
JP7022080B2
(ja)
|
2016-05-27 |
2022-02-17 |
ジェネンテック, インコーポレイテッド |
部位特異的抗体-薬物複合体の特徴付けのための生化学分析的方法
|
WO2017214182A1
(fr)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Anticorps entièrement humain ciblant pdi pour l'immunothérapie anticancéreuse
|
EP3494135A1
(fr)
|
2016-08-02 |
2019-06-12 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Anticorps monoclonaux ciblant le glypican-2 (gpc2) et leur utilisation
|
CN109963868B
(zh)
|
2016-08-22 |
2023-11-14 |
醣基生医股份有限公司 |
抗体、结合片段及使用方法
|
AU2017321894A1
(en)
|
2016-09-02 |
2019-03-14 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with duoCARs
|
GB201615725D0
(en)
|
2016-09-15 |
2016-11-02 |
Polytherics Ltd |
Novel cytotoxic agents and conjugates thereof
|
KR102221364B1
(ko)
|
2016-11-21 |
2021-03-04 |
쿠레아브 게엠베하 |
항-gp73 항체 및 면역접합체
|
CA3045902A1
(fr)
|
2016-12-21 |
2018-06-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticorps monoclonaux humains specifiques a la flt3 et leur utilisation
|
EP4183798A1
(fr)
|
2017-01-09 |
2023-05-24 |
Lentigen Technology, Inc. |
Compositions et procédés pour le traitement du cancer avec immunothérapie anti-mésothéline
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
US10426797B2
(en)
|
2017-03-24 |
2019-10-01 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD33 immunotherapy
|
WO2018185618A1
(fr)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Conjugués de médicament-anticorps anti-cdh6 et combinaisons d'anticorps anti-gitr et méthodes de traitement
|
AU2018268970A1
(en)
|
2017-05-19 |
2019-10-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
|
AR111963A1
(es)
|
2017-05-26 |
2019-09-04 |
Univ California |
Método y moléculas
|
WO2019005208A1
(fr)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticorps de la mésothéline humaine et utilisations dans une thérapie anticancéreuse
|
CA3066953A1
(fr)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
Anticorps monoclonaux humains specifiques de cd33 et leurs procedes d'utilisation
|
JP7237926B2
(ja)
|
2017-07-31 |
2023-03-13 |
レンティジェン・テクノロジー・インコーポレイテッド |
抗cd19/cd20免疫療法によりがんを処置するための組成物および方法
|
CN107446050A
(zh)
|
2017-08-11 |
2017-12-08 |
百奥泰生物科技(广州)有限公司 |
Trop2阳性疾病治疗的化合物及方法
|
US10501539B2
(en)
|
2017-09-15 |
2019-12-10 |
Lentigen Technology Inc. |
Compositions and methods for treating cancer with anti-CD19 immunotherapy
|
JP7275118B2
(ja)
|
2017-10-16 |
2023-05-17 |
レンティジェン・テクノロジー・インコーポレイテッド |
抗cd22免疫療法によってがんを処置するための組成物および方法
|
CN111954677A
(zh)
|
2017-12-20 |
2020-11-17 |
莱蒂恩技术公司 |
用于用免疫治疗来治疗hiv/aids的组合物和方法
|
EP3820903A1
(fr)
|
2018-07-12 |
2021-05-19 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Anticorps monoclonal spécifique pour cd22 à maturation par affinité et utilisations associées
|
CA3107383A1
(fr)
|
2018-07-23 |
2020-01-30 |
Magenta Therapeutics, Inc. |
Utilisation d'un conjugue anticorps anti-cd5 -medicament (adc) dans une therapie cellulaire allogenique
|
WO2020033430A1
(fr)
|
2018-08-08 |
2020-02-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticorps monoclonaux à haute affinité ciblant le glypicane-2 et leurs utilisations
|
CN118291501A
(zh)
|
2018-09-20 |
2024-07-05 |
莱蒂恩技术公司 |
用于用抗cd123免疫治疗来治疗癌症的组合物和方法
|
CA3114349A1
(fr)
|
2018-09-26 |
2020-04-02 |
Lentigen Technology, Inc. |
Compositions et procedes de traitement du cancer par immunotherapie anti-cd19/cd22
|
US11103533B2
(en)
|
2018-11-30 |
2021-08-31 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD38 immunotherapy
|
AU2018451747A1
(en)
|
2018-12-06 |
2021-06-17 |
F. Hoffmann-La Roche Ag |
Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugates, an alkylating agent and an anti-CD20 antibody
|
CN113490510A
(zh)
|
2019-01-08 |
2021-10-08 |
美国政府(由卫生和人类服务部的部长所代表) |
用于治疗实体瘤的靶向间皮素的跨物种单结构域抗体
|
AU2020212534A1
(en)
|
2019-01-22 |
2021-07-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-1 and methods of use
|
US11969443B2
(en)
|
2019-03-06 |
2024-04-30 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with self-driving chimeric antigen receptors
|
US20220133904A1
(en)
|
2019-03-19 |
2022-05-05 |
Paul Scherrer Institut |
Transglutaminase conjugation method with a glycine based linker
|
BR112021022815A2
(pt)
|
2019-05-14 |
2021-12-28 |
Genentech Inc |
Métodos para tratar linfoma folicular, kits, imunoconjugados e polatuzumabe vedotina
|
CN114364801B
(zh)
|
2019-05-30 |
2024-04-19 |
莱蒂恩技术公司 |
用于用抗bcma免疫治疗来治疗癌症的组合物和方法
|
CN114269783B
(zh)
|
2019-07-02 |
2024-03-26 |
美国政府(由卫生和人类服务部的部长所代表) |
结合egfrviii的单克隆抗体及其应用
|
JPWO2021010326A1
(fr)
|
2019-07-12 |
2021-01-21 |
|
|
EP4045090A1
(fr)
|
2019-10-18 |
2022-08-24 |
Genentech, Inc. |
Procédés d'utilisation d'immunoconjugués anti-cd79b pour traiter un lymphome diffus à grandes cellules b
|
EP4031250A1
(fr)
|
2019-10-22 |
2022-07-27 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Nanocorps à haute affinité ciblant b7h3 (cd276) pour traiter des tumeurs solides multiples
|
WO2021118968A1
(fr)
|
2019-12-12 |
2021-06-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Conjugués anticorps-médicament spécifiques à cd276 et leurs utilisations
|
CA3175530A1
(fr)
|
2020-04-24 |
2021-10-28 |
Genentech, Inc. |
Procedes d'utilisation d'immunoconjugues anti-cd79b
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
AU2021296423A1
(en)
|
2020-06-22 |
2023-02-02 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy
|
JP2023542910A
(ja)
|
2020-09-18 |
2023-10-12 |
アラリス バイオテック アーゲー |
アミノ酸に基づくリンカーを使用したトランスグルタミナーゼコンジュゲーション方法
|
EP4232095A1
(fr)
|
2020-10-25 |
2023-08-30 |
Araris Biotech AG |
Moyens et procédés de fabrication de conjugués anticorps-lieur
|
WO2022093745A1
(fr)
|
2020-10-26 |
2022-05-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticorps à domaine unique ciblant une protéine de spicule de coronavirus responsable du sars et leurs utilisations
|
AU2021372997A1
(en)
|
2020-11-05 |
2023-06-22 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
|
US20240218055A1
(en)
|
2021-04-29 |
2024-07-04 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
WO2022241446A1
(fr)
|
2021-05-12 |
2022-11-17 |
Genentech, Inc. |
Méthodes d'utilisation d'immunoconjugués anti-cd79b pour traiter un lymphome diffus à grandes cellules b
|
CA3220227A1
(fr)
|
2021-05-28 |
2022-12-01 |
Matthew Bruce |
Polytherapies pour traiter le cancer
|
EP4352099A1
(fr)
|
2021-06-09 |
2024-04-17 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Anticorps à domaine unique hétérospécifiques ciblant pd-l1 pour le traitement de tumeurs solides
|
US11807685B2
(en)
|
2021-08-05 |
2023-11-07 |
The Uab Research Foundation |
Anti-CD47 antibody and uses thereof
|
TW202337499A
(zh)
|
2021-08-07 |
2023-10-01 |
美商建南德克公司 |
使用抗cd79b免疫結合物治療瀰漫性大b細胞淋巴瘤之方法
|
WO2023057893A1
(fr)
|
2021-10-05 |
2023-04-13 |
Glaxosmithkline Intellectual Property Development Limited |
Polythérapies pour le traitement du cancer
|
CN118159298A
(zh)
|
2021-10-25 |
2024-06-07 |
阿拉里斯生物技术股份公司 |
生产抗体-接头偶联物的方法
|
WO2023161291A1
(fr)
|
2022-02-22 |
2023-08-31 |
Araris Biotech Ag |
Liaisons peptidiques comprenant deux ou plusieurs charges utiles
|
US11590169B1
(en)
|
2022-03-02 |
2023-02-28 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
US20230338424A1
(en)
|
2022-03-02 |
2023-10-26 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
|
WO2024026107A2
(fr)
|
2022-07-28 |
2024-02-01 |
Lentigen Technology, Inc. |
Thérapies par récepteur antigénique chimérique pour le traitement de tumeurs solides
|
WO2024044743A1
(fr)
|
2022-08-26 |
2024-02-29 |
Lentigen Technology, Inc. |
Compositions et méthodes de traitement du cancer par immunothérapie anti-cd20/cd19 entièrement humaine
|